– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –
BUBBA® App to Exclusively Launch MLF® SCORETRACKER LIVE Beginning Spring 2026
COLUMBIA, Mo. and BENTON, Ky., July 14, 2025 /PRNewswire/ -- BUBBA, a leading fishing brand known...
The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate...
The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate...
The VARIPULSE™ Platform is the first Pulsed Field Ablation (PFA) system fully integrated with the CARTO™ 3 electroanatomical mapping system, designed to drive efficiency,...
OTTAWA, ON, July 4, 2025 /CNW/ - The Canadian Food Inspection Agency (CFIA) has confirmed the presence of the aquatic animal diseases multinucleate sphere...